Skip to Main Content

Paper Details

Phase 1b, open-label study evaluating the safety and pharmacokinetics of atezolizumab (anti-PD-L1 antibody) administered in combination with Hu5F9-G4 to patients with relapsed and/or refractory acute myeloid leukemia.
Leuk Lymphoma
7
2022

Datasets

Release 1.2